All In Biotech

Drug Trial Radar · NCT05765851

A Study of DS-1103a Combination Therapy in Participants With Advanced Solid Tumors

A Phase 1, 2-Part, Multicenter, First-In-Human Dose-Escalation and Dose-Expansion Study of DS-1103a Combination Therapy in Subjects With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

128

Planned (sponsor's estimate)

Start

May 30, 2023

Primary completion

May 31, 2029

Study completion Feb 28, 2031

Sponsor

Lead sponsor
Daiichi SankyoDaiichi Sankyo (DSNKY)
Sponsor type
Industry
Collaborators
AstraZeneca
First posted
Mar 13, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the safety and efficacy of DS-1103a combination therapy in participants with advanced solid tumors.

Conditions

  • Advanced Solid Tumor

Interventions

  • DS-1103aDrug

    One IV infusion Q3W on Day 1 of each 21-day cycle

  • T-DXdDrug

    One IV infusion Q3W on Day 1 of each 21-day cycle

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Dose-limiting Toxicities (Dose Escalation)Time frame: From Cycle 1 Day 1 to Cycle 2 Day 21 (each cycle is 21 days)
  2. Objective Response Rate Assessed by Blinded Independent Central Review Following DS-1103a Combination Therapy (Dose Expansion)Time frame: Baseline (Dose Expansion) up until documented progressive disease, unacceptable toxicity, death, lost to follow-up, or withdrawal by the participant, up to approximately 5 years 11 months
  3. Number of Participants with Dose-limiting Toxicities Following DS-1103a Combination Therapy (Dose Expansion; Cohort 2 Safety Run In and Japanese Population Tolerability Assessments)Time frame: From Cycle 1 Day 1 to Cycle 1 Day 21 (each cycle is 21 days)
  4. Overall Number of Participants With Treatment-emergent Adverse Events and Serious Adverse Events (Dose Escalation and Expansion; Cohort 2 Safety Run In and Japanese Population Tolerability Assessments)Time frame: Screening through long-term follow up, up to approximately 91 months

Locations

15 sites in 6 countries. Site status is shown where the registry gives one.

  • Florida Cancer Specialists

    Sarasota, Florida · Recruiting

  • Memorial Sloan Kettering Cancer Center

    New York, New York · Recruiting

  • Lifespan Cancer Institute

    Providence, Rhode Island · Recruiting

  • University of Utah

    Salt Lake City, Utah · Recruiting

  • NEXT Oncology

    Fairfax, Virginia · Recruiting

  • Princess Margaret Cancer Centre, University Health Network

    Toronto, Canada · Recruiting

  • Centre Léon Bérard

    Lyon, France · Recruiting

  • Oncopole - Institut Claudius Regaud

    Toulouse, France · Recruiting

  • Gifu University Hospital

    Gifu, Japan · Recruiting

  • Shizuoka Cancer Center

    Nakatogari, Japan · Recruiting

  • The University of Osaka Hospital

    Osaka, Japan · Recruiting

  • The Cancer Institute Hospital Of JFCR

    Tokyo, Japan · Recruiting

  • Hospital Universitari Vall d'Hebron

    Barcelona, Spain · Recruiting

  • National Cheng Kung University Hospital

    Tainan, Taiwan · Recruiting

  • Taipei Veterans General Hospital

    Taipei, Taiwan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.